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The oncoprotein kinase Tpl2 plays an essential role in macrophage activation by the bacterial component lipopolysaccharide (LPS). In
response to LPS stimulation, Tpl2 phosphorylates a downstream kinase, MEK1, leading to the activation of ERK signaling pathway. Recent
studies demonstrate that the NF-κB1 precursor protein p105 functions as an inhibitor of Tpl2 and that the LPS-stimulated Tpl2 activation requires
p105 degradation. However, how p105 inhibits the signaling function of Tpl2 is not completely understood. We show here that p105 does not
inhibit the intrinsic kinase activity of Tpl2. When complexed with p105, Tpl2 remains catalytically active and uses p105 as a substrate. However,
the p105-bound Tpl2 is unable to phosphorylate its physiological target, MEK1. These findings suggest that p105 functions as a competitive
inhibitor of Tpl2 that blocks its access by MEK1.
© 2005 Elsevier B.V. All rights reserved.Keywords: Tpl2; Cot; NF-κB1; p105; IKK; MAPK1. Introduction
Tpl2, also known as Cot, was originally identified as a
protooncoprotein kinase, whose overexpression and structural
alterations induce cell transformation and lymphoid malignan-
cies [1,2]. Tpl2 is a member of the MAP kinase kinase kinase
(MAP3K) family known to regulate activation of MAP kinase
signaling pathways [3]. Genetic evidence suggests that Tpl2 is
essential for lipopolysaccharide (LPS)-stimulated activation of
MAP kinase kinase 1 (MEK1) and its downstream target,
extracellular signal-regulated kinase (ERK) [4]. In certain cell
types, Tpl2 also plays a role in regulating activation of the
transcription factor NF-κB [5]. Unlike the MAP3K Raf-1 that
regulates the classical MEK/ERK pathway, Tpl2 does not
respond to mitogens [6] but acts as a target of various immune⁎ Corresponding author. Fax: +1 717 531 6522.
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doi:10.1016/j.bbamcr.2005.12.010stimuli, including the bacterial component LPS, the proin-
flammatory cytokine TNF-α, and the B-cell stimulator CD40
ligand [4,6–8]. The Tpl2 signaling pathway plays a pivotal role
in regulating the production of proinflammatory mediators by
macrophages, antibody isotype switching in B cells, and activ-
ation of dendritic cells [4,7–9].
Recent studies reveal that the function of Tpl2 is tightly
regulated by the nfκb1 gene product p105 [6,10]. In macro-
phages and various other cell types, Tpl2 is present as a stable
complex with p105 as well as another protein, ABIN-2 [6,10–
12]. Within this latent kinase complex, p105 functions to both
stabilize Tpl2 and inhibit the kinase function of Tpl2. Thus,
p105 is considered as a physiological partner and inhibitor of
Tpl2 [6,10]. Consistently, activation of Tpl2 by LPS and TNF-α
involves the dissociation of Tpl2 from p105 and the post-
activation degradation of Tpl2 [6,10]. Biochemical and genetic
evidence suggests that the signal-induced liberation of Tpl2
requires proteasome-mediated degradation of p105. This mole-
cular event is in turn triggered through site-specific phosphor-
ylation of p105 by the IκB kinase (IKK) [13,14]. The signal-
induced activation of Tpl2 may also involve its phosphorylation
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on IKK [16].
IKK is known as a signaling molecule that mediates
activation of the transcription factor NF-κB [17]. The canonical
target of IKK is the NF-κB inhibitory protein IκBα. IKK
phosphorylates two specific serines of IκBα, which targets this
inhibitory protein for ubiquitination and proteolysis by the
proteasome. The C-terminal region of p105 contains a serine
cluster that is homologous to the IKK phosphorylation sequence
in IκBα. Indeed, p105 has been shown to serve as a target of
IKK [18–20]. Mutation of the IKK phosphorylation sites of
p105 abrogates its degradation in LPS-stimulated macrophages
as well as blocks the liberation and activation of Tpl2 [13,14].
Thus, one pivotal step in Tpl2 activation is signal-induced p105
degradation. Despite the significant progress in IKK-mediated
p105 phosphorylation, there are still important missing links in
the Tpl2/p105 molecular interplay. In particular, it is unclear
how p105 inhibits the signaling function of Tpl2. In this study,
we show that p105 does not inhibit the intrinsic kinase activity
of Tpl2. Interestingly, the p105-associated Tpl2 is catalytically
active and uses p105 as an intracomplex substrate. However,
when complexed with p105, the active Tpl2 is unable to
phosphorylate its physiological substrate, MEK1.
2. Materials and methods
2.1. Plasmid constructs and GST fusion proteins
GST-IκBα(1–54) has been described [21]. The pcDNA-HA-Tpl2 was
generated by PCR-based cloning of the human Tpl2 cDNA into pcDNA-HA
vector [22]. The expression vector encoding untagged p105 (pCMV4-p105) was
provided by Dr. Warner Greene. The p105 truncation mutants were generated by
PCR and cloned into the pcDNA expression vector downstream a HA tag. GST-
MEK1 was constructed by cloning human MEK1 into the pGEX4T-3 vector
(Amersham/Pharmacia Biotech), and the GST-p105(435–969) and other GST-
p105 truncation mutants were generated by cloning the indicated regions of
p105 into the pGEX4T-1 vector. Internal deletion mutants were created by site-
directed mutagenesis (Stratagene) using GST-p105(435–802) as template. The
oligonucleotide primers for PCR and site-directed mutagenesis (sequences are
available upon request) were synthesized at the Macromolecular Core of Penn
State University College of Medicine. All the plasmids used in this work were
sequenced at the Molecular Genetics Core of Penn State University College of
Medicine. GST fusion proteins were produced in bacteria and purified using
glutathione-conjugated Sepharose beads (Amersham/Pharmacia Biotech) fol-
lowing the manufacturer's instruction.
2.2. Antibodies and other reagents
The C-terminal specific anti-p105 antibody (anti-p105C) was provided by
Dr. Nancy Rice. Anti-HA (12CA5) and HRP-conjugated HA antibody (3F10)
were from Roche Molecular Biochemicals. The antibody for Tpl2 (anti-Cot
M20), HRP-conjugated anti-Tpl2, and anti-GST were from Santa Cruz. The
IKKβ inhibitor PS1145 was provided byMillennium Pharmaceuticals, Inc. [23].
LPS derived from E. coli 0127:B8 was obtained from Sigma, and MG132 was
from Alexis.
2.3. Cell culture and transfection
Bone marrow derived macrophages (BMDM) were prepared and cultured as
previously described [6]. The murine RAW264 macrophage cell line was from
ATCC and cultured in Dulbecco's medium supplemented with 10% FCS and
antibiotics. Human embryonic kidney carcinoma 293 cells were cultured in the
same medium and transfected in 6-well plates using Lipofectamine 2000(Invitrogen). The mouse embryonic fibroblasts (MEFs) derived from wildtype
and IKK knockout mice were provided by Dr. Michael Karin, and the MEF
derived from Tpl2 knockout mice was provided by Dr. Philip Tsichlis.
2.4. In vitro translation
The pcDNA based HA-Tpl2 was translated in vitro using the Rabbit
Reticulocyte Lysate TNT Coupled Transcription/Translation System (Promega)
following the manufacturer's instructions.
2.5. Immunoblotting (IB) and in vitro kinase assays
Cell lysates were prepared by lysing the cells in a kinase cell lysis buffer
containing 20 mM HEPES (pH 7.6), 250 mM NaCl, 0.5% NP-40, 20 mM β-
glycerophosphate, 1 mM EDTA, 5 mg/ml p-nitrophenylphosphate (PNPP), 0.1
mM Na3VO4, 1 mM dithiothreitol (DTT), 1 mM phenylmethylsulfonyl fluoride
(PMSF), and a protease inhibitor cocktail (Sigma). Where indicated, the buffer
was also supplemented with 0.1% SDS to remove the loosely associated proteins
from the immune complex. The p105 and Tpl2 immune complexes were isolated
from cell lysates or in vitro translation mix by immunoprecipitation (IP) and
subjected to kinase assays as described previously [21]. Briefly, the IP beads
were washed three times with kinase cell lysis buffer and twice with kinase
reaction buffer (20 mM HEPES, pH 7.6, 20 mM MgCl2, 20 mM β-glycero-
phosphate, 1 mM EDTA, and 2 mM DTT). Kinase assays were initiated by
addition to the beads of 30 μl kinase reaction buffer containing 20 μM ATP, 2
mM DTT, 2.5 μCi γ32P-ATP, and 1 μg substrates (GST-MEK1 or GST-p105
proteins). For detection of p105-associated kinases, the kinase assay reaction
was carried out without exogenous substrates. After 30 min of incubation at 30
°C, the phosphorylated substrates and other proteins in the immunecomplexes
were fractionated by SDS-PAGE and visualized by autoradiography. For IB
assays, cell lysates were subjected to SDS-PAGE, and the proteins were
transferred onto nitrocellulose and detected by specific antibodies using the
Enhanced Chemiluminescence Reagent (PerkinElmer Life Sciences, Inc.).
2.6. GST pulldown assays
In vitro translated Tpl2 (4 μl) was incubated with 1 μg of the indicated GST-
p105 mutants on ice for 30 min. The GST-p105 proteins and associated Tpl2
were then precipitated with 30 μl of glutathione agarose in 500 μl of RIPA buffer
by rotating overnight in a cold room. After washing the beads for three times
with RIPA buffer, the protein complexes were eluted in 2× SDS loading buffer
and fractionated by SDS-PAGE. The precipitated Tpl2 was detected by IB using
HRP-anti-HA.3. Results
3.1. p105 is physically associated with a specific kinase
To understand the mechanism of p105 phosphorylation, we
carried out studies to determine whether p105 is physically
associated with IKK or other kinases. The p105 protein
complex was isolated from BMDM by IP followed by in vitro
kinase assays. Interestingly, p105 was potently phosphorylated
within the immunecomplex isolated from unstimulated macro-
phages (Fig. 1A, upper panel, lanes 1–5), suggesting its phy-
sical association with an active kinase. Stimulation of cells with
LPS did not enhance the p105-specific kinase activity (lanes 3–
5). In fact, the phosphorylation of p105 diminished along with
LPS stimulation. Similar results were obtained with a murine
macrophage cell line, RAW264 (Fig. 1A, lanes 6–9). These
results were not due to accidental exposure of the cells to
endotoxin, since IB assays demonstrated normal induction of
ERK phosphorylation by LPS (Fig. 1B). Further, LPS also
Fig. 1. The p105 immune complex contains a constitutive p105 kinase that is not IKK. (A) P105 is physically associated with a constitutive kinase. BMDM or
RAW264 cells were either not treated (NT) or stimulated for the indicated times with LPS (2.5 μg/ml). The p105 complex was isolated by IP using anti-p105C or a
control preimmune serum (PI) followed by kinase assays (KA) to examine the intracomplex phosphorylation of p105. Following autoradiography, the kinase assay
membrane was subjected to IB to monitor the amount of p105 protein. The phosphorylated p105 (p105-P) and total p105 protein (p105) are indicated. (B) Normal
activation of ERK in the BMDM and RAW264 cells. The cells were stimulated as in A and subjected to IB using a phospho-specific (αERK-P) or regular (αERK) anti-
ERK antibodies. (C) LPS-stimulated reduction of p105 phosphorylation is due to its degradation. RAW264 cells were preincubated for 30 min either in the absence (−)
or presence (+) of the proteasome inhibitor MG132 (25 μM). The cells were then either not treated (NT) or stimulated for 30 min with LPS (2.5 μg/ml). Kinase assays
and IB were performed as described in B. (D) The p105-associated kinase is not IKK. The p105 immune complexes were isolated from nontreated (NT) or LPS-
stimulated RAW264 cells. The immune complexes were incubated in vitro for 60 min in the absence (−) or presence (+) of 10 μM PS1145. Protein kinase assays were
performed in the presence of a typical IKK substrate, GST-IκBα (1–54). The phosphorylated p105 (top panel) and IκBα (middle panel) are indicated. The level of
p105 protein was detected by IB using anti-p105C (bottom panel). (E) The p105-associated kinase is also present in IKK-deficient cells. The p105 immunecomplex
was isolated by IP from wildtype (WT) MEFs or the indicated mutant MEFs lacking different IKK subunits, followed by kinase assays as described in A.
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contributed to the reduction of p105 phosphorylation in the
immunecomplex. In support of this idea, inhibition of p105
degradation by a proteasome inhibitor, MG132, greatly en-
hanced the phosphorylation of p105 (Fig. 1C, lane 3). These
results suggest that a p105-specific kinase is present in the p105
protein complex and that this complex is dissociated upon LPS
stimulation due to degradation of p105.
3.2. The p105-associated kinase is not IKK
Prior studies suggest that p105 is physically associated with
IKK and is phosphorylated by IKK in response to cellular
stimuli, including the inflammatory cytokines TNF-α and inter-
leukin 1 [18,19,24]. Since the p105-associated kinase was
detected in unstimulated cells, we reasoned that it might not be
IKK. To further examine this idea, we analyzed whether the
p105 immunecomplex has IκB-specific kinase activity by in
vitro kinase assays using IκBα as substrate. As expected, p105
was phosphorylated in the immunecomplex isolated from
untreated macrophages (Fig. 1D, upper panel, lane 1). In con-
trast, IκBα was not phosphorylated under the same conditions
(lower panel, lane 1). Aweak IκB-phosphorylating activity was
detected in the p105 complex isolated from LPS-stimulated
cells (lane 3). This kinase activity appeared to be contributed by
IKK, since it was inhibited by an IKKβ inhibitor, PS1145 (lane
4). This finding was consistent with the previous observation
that p105 physically associates with IKK [20,25,26]. Impor-tantly, however, IKK did not seem to contribute to the potent
phosphorylation of p105, since the p105-specific kinase activity
was not inhibited by the IKK inhibitor PS1145 (upper panel,
lane 4). The seemingly enhancing activity of PS1145 on p105
phosphorylation occurred only in certain experiments and thus
might represent variation. Consistently, the p105-associated
kinase was also detected in mouse embryonic fibroblasts (MEF)
lacking different IKK subunits (Fig. 1E). The level of p105
phosphorylation was even higher in the IKKγ-deficient cells,
which was likely due to the higher expression level of p105
protein.
3.3. The p105 kinase is Tpl2
A common characteristic of protein kinases is their ability
to autophosphorylate. As an approach to identify the p105-
associated kinase, we performed in vitro kinase assays to detect
phosphorylated proteins within the p105 immune complex.
Several phosphorylated proteins could be detected in the immu-
necomplex kinase assays when extended autoradiography was
carried out (Fig. 2A, upper panel, lanes 1–3). However, only two
distinctive bands were retained when the IPwas performed in the
presence of a low percentage of SDS (lanes 4–6, arrows).
Moreover, the phosphorylation pattern of these two p105-
associated proteins was comparable to that of p105. Based on the
molecular mass of these two proteins, we suspected them to be
the two different isoforms of Tpl2, Tpl2L and Tpl2S. To confirm
this possibility, we performed IB assays to examine the presence
Fig. 2. The p105-associated kinase is Tpl2. (A) RAW264 cells were preincubated for 30 min with (+) or without (−) MG132 followed by another 30 min of incubation
in the absence (−) or presence (+) of LPS. The p105 immune complexes were isolated by IP using anti-p105C either in the absence (−) or presence (+) of 0.1% SDS.
Protein kinase assays (upper panel) were performed as described in Fig. 1 to examine the phosphorylation of p105 and other associated proteins. The arrows indicate
two major phosphorylated proteins associated with p105. Following autoradiography, the kinase assay membrane was subjected to IB using an HRP-conjugated anti-
Tpl2 antibody (lower panel). The p105-associated Tpl2 isoforms are indicated. (B) P105 is phosphorylated by wildtype Tpl2 but not a catalytically inactive Tpl2
mutant. 293 cells were transfected with HA-tagged p105 together with either an empty pcDNA vector or expression vectors encoding HA-tagged wildtype (WT) or
kinase dead mutant (Mut) of Tpl2. The p105/Tpl2 complex was isolated by IP using anti-HA followed by kinase assays to examine the phosphorylation of p105 (p105-
P) and autophosphorylation of Tpl2 (Tpl2-P). The expression levels of p105 and its processed product p50 as well as Tpl2 were measured by IB using anti-HA. Note
that only the TplL was detected in IB, since the HA epitope was tagged to the N-terminus of Tpl2 (absent in Tpl2S). The detection of Tpl2S in the kinase assay was due
to its association with p105. Since both p105 and Tpl2 were tagged with HA, we initially performed control experiments that helped in identification of the different
protein bands (data not shown). (C) Tpl2 is essential for p105 phosphorylation. P105 immune complexes were isolated from wildtype (WT), Tpl2-deficient, or NF-
κB1-deficient MEFs followed by in vitro kinase assays to measure phosphorylation of p105 (p105-P) and autophosphorylation of Tpl2 (Tpl2L-P, Tpl2S-P). The kinase
assay membrane was subjected to IB using anti-p105C to detect the p105 protein (lower panel).
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stringent IP conditions. Indeed, significant amounts of Tpl2L and
Tpl2S remained associated with p105 even in the presence of a
low amount of SDS (Fig. 2A, lower panel, lanes 4–6). Further, as
previously reported [6,10], the Tpl2L/p105 complex was rapidly
lost upon cellular stimulation by LPS (lanes 2 and 5) and this
dynamic change was blocked by the proteasome inhibitor
MG132 (lanes 3 and 6). More importantly, the amount of Tpl2 in
the p105 immune complex tightly correlated with the level of
p105 phosphorylation.
To further investigate whether Tpl2 phosphorylates p105, we
transfected p105 into 293 cells together with either wildtype
Tpl2 or a catalytically inactive Tpl2 mutant. In the cells
transfected with p105 alone, p105 did not coprecipitate with
detectable amounts of kinase activity (Fig. 2B, upper panel, lane
1), which was likely due to the overexpression of p105 and the
low level of endogenous Tpl2 in 293 cells. However, when
p105 was coexpressed with wildtype Tpl2, potent activity of
p105 phosphorylation and Tpl2 autophosphorylation were
detected in the in vitro kinase assays (lane 2). In contrast, the
kinase dead mutant of Tpl2 failed to phosphorylate p105 or
undergo autophosphorylation (lane 3). We next sought to obtain
genetic evidence that Tpl2 was the p105 kinase by using Tpl2-
deficient MEFs. As expected, the p105 immune complex iso-
lated from wildtype MEFs exhibited strong p105 kinase activity
as well as Tpl2 autophosphorylation activity (Fig. 2C, upper
panel, lane 1). In sharp contrast, the p105-specific kinase
activity was not detected in the immune complex isolated from
Tpl2 knockout MEFs (lane 2), although p105 was present in theimmune complex (Fig. 2C, lower panel, lane 2). Together, these
results provide biochemical and genetic evidence for p105
phosphorylation by Tpl2.
3.4. The Tpl2 phosphorylation site within p105 differs from
that phosphorylated by IKK
We next performed deletion analyses to localize the region
within p105 that is phosphorylated by Tpl2. N-terminal trun-
cation analyses showed that the Rel homology domain of p105
was dispensable for its phosphorylation by Tpl2 (Fig. 3A). A
mutant containing amino acid 370–969 remained competent in
serving as the substrate of Tpl2 (Fig. 3A, lane 7), although the
result for a shorter mutant (435–969) was difficult to interpret
due to its comigration with Tpl2L (lane 9). To overcome this
technical challenge, we produced a GST fusion protein con-
taining p105(435–969) using bacterial expression system. This
purified fusion protein was readily phosphorylated by Tpl2
isolated from either transfected 293 cells or in vitro translation
system (Fig. 3B). Thus, deletion of the entire Rel-homology
domain of p105 did not affect its phosphorylation by Tpl2.
To map the N- and C-terminal boundaries of the Tpl2 phos-
phorylation site within p105, we introduced additional trunca-
tions to the GST-p105(435–969). Deletion of up to 239 amino
acids from the C-terminus of p105 did not reduce its phospho-
rylation by Tpl2 (Fig. 3C, upper panel, lanes 2 and 3). Of note,
the deleted region contains the known phosphorylation sites for
IKK [18,19,24]. This result suggests that the Tpl2 phosphor-
ylation site within p105 differs from that for IKK. Further
Fig. 3. The Tpl2 phosphorylation sites within p105 differ from those phosphorylated by IKK. (A) The N-terminal portion of p105 is dispensable for phosphorylation by
Tpl2. Full length (FL) or the indicated N-terminal truncation mutants of p105 (HA-tagged) were transfected into 293 cells together with either an empty pcDNAvector
or the HA-tagged Tpl2. The p105/Tpl2 complexes were isolated by IP using anti-HA followed by kinase assays. Phosphorylated p105 and its mutants as well as Tpl2
isoforms are indicated. The Tpl2S that was precipitated by p105 IP was either endogenous protein or produced from the transfected Tpl2. This short isoform was not
detected by IP using the HA antibody (see B), since it lacks the N-terminus. (B) Tpl2 was isolated by IP (using anti-HA) from either transfected 293 cells or in vitro
translation mix. As negative controls, an empty vector was used for the 293 cell transfection and in vitro translation. Protein kinase assay were performed using a GST
fusion protein containing the C-terminal portion (amino acids 435–969) of p105 (p105C). The phosphorylated p105C and Tpl2 are indicated (upper panel). The Tpl2
protein level was monitored by IB (lower panel). (C) The region covering amino acids 542–613 of p105 is required for its phosphorylation by Tpl2. GST fusion
proteins containing the indicated p105 mutants were subjected to kinase assays using in vitro translated Tpl2. The phosphorylated p105 mutants as well as
autophosphorylated Tpl2 are indicated (top panel). The protein level of the GST-p105 mutants was measured by IB using anti-GST (middle panel). The Tpl2-binding
activity of the p105 mutants were determined by a GST pulldown assay (bottom panel). (D) Summary of results presented in C. RHD, rel-homology domain; AKR,
ankyrin repeats; DD, death domain.
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no longer phosphorylated by Tpl2 (lane 4). Small internal
deletions demonstrated that removal of the region covering
amino acids 542–613 abolished p105 phosphorylation (lane 7),
whereas deletion of the more downstream regions (amino acids
685–700 and 714–733) did not significantly affect p105
phosphorylation (lanes 8 and 9). In parallel, we also examined
the Tpl2-binding function of the p105 mutants by GST pull-
down assays. As expected from the previous studies [6,10],
p105 (435–969) strongly interacted with Tpl2 (Fig. 3B, bottom
panel, lane 1). Furthermore, a shorter p105 mutant (435–802),
lacking the death domain (located between amino acids 805 and
892) and C-terminal region, failed to bind Tpl2 (lane 2). How-
ever, as demonstrated in various other in vitro kinase assays, the
stable association of substrate with kinases was not a require-
ment for substrate phosphorylation since p105 (435–802) was
efficiently phosphorylated by Tpl2 (Fig. 3B, top panel, lane 2).
Similar analyses revealed that the shorter p105 mutants harbor-
ing truncations or internal deletions either weakly interacted orfailed to interact with Tpl2. Together, these results, as
summarized in Fig. 3D, suggest that the region covering
amino acids 542 to 613 of p105 is critical for its phosphory-
lation by Tpl2.
3.5. P105 appears to function as a competitive inhibitor of Tpl2
We and others have previously shown that p105 functions as
an inhibitor of Tpl2 [6,10], although how p105 interferes with
the kinase function of Tpl2 is unclear. The findings described
above prompted us to examine whether p105 inhibits the intrin-
sic catalytic activity of Tpl2 or acts through other mechanisms.
For these studies, Tpl2 was expressed in 293 cells either alone or
together with p105, and the catalytic activity of Tpl2 was
determined by immunecomplex kinase assays using recombi-
nant MEK1 as substrate. As expected from prior studies, p105
potently inhibited the ability of Tpl2 to phosphorylate MEK1
(Fig. 4A, panel 2). The autophosphorylation activity of Tpl2 was
also reduced but not completely blocked (panel 3), which was
Fig. 4. P105 does not inhibit the intrinsic catalytic activity of Tpl2 but prevents Tpl2 from phosphorylating MEK1. (A) 293 cells were transfected with either an empty
vector or HA-tagged Tpl2 (250 ng) together with the indicated amounts of p105. The p105/Tpl2 complex was isolated by IP (using anti-HA) followed by kinase assays
(KA) using GST-MEK1 as substrate. The phosphorylated p105 (p105-P) and MEK1 (GST-MEK1-P) as well as autophosphorylated Tpl2 (HA-Tpl2-P) are indicated
(top three panels). The level of p105 and Tpl2 proteins was detected by IB using anti-p105C and anti-HA, respectively (bottom two panels). (B) The p105-bound Tpl2
phosphorylates p105 but not MEK1. RAW264 cells were either not treated (NT) or stimulated for the indicated times with LPS. The protein lysates were subjected to
IP using either a preimmune serum (PI) or anti-p105C. The isolated p105/Tpl2 complex was subjected to kinase assays in the presence of GST-MEK1 substrate. Note
that p105, but not GST-MEK1, was phosphorylated by the p105-bound Tpl2. The basal phosphorylation of GST-MEK1 was due to its autophosphorylation, since it
was also detected in the kinase assay lacking Tpl2 (lane 1). (C) p105 is more efficient than MEK1 in phosphorylation by Tpl2. Kinase assays were performed using in
vitro translated HA-Tpl2 in the presence of a constant amount of GST-MEK1 (400 ng) and the indicated amounts of GST-p105 (435–969) or GST-p105 (435–541).
The phosphorylated p105 (435–969) andMEK1 as well as autophosphorylated Tpl2 are indicated (upper panel). P105 (435–541) was not phosphorylated. The level of
the different proteins was analyzed by IB using anti-HA together with anti-GST (lower panel).
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activity in the p105/Tpl2 immune complex (Fig. 2). More
importantly, along with the inhibition ofMEK1 phosphorylation
and Tpl2 autophosphorylation, p105 was potently phosphory-
lated by Tpl2 (top panel, lanes 3 and 4). These results demon-
strate that p105 does not inhibit the intrinsic catalytic activity of
Tpl2 but may function as a competitive inhibitor to prevent Tpl2
from phosphorylating its substrate MEK1.
We also performed similar kinase assays using endogenous
p105/Tpl2 complexes isolated from RAW264 macrophage
cells. Consistent with the results presented in Fig. 1A, the
p105-associated Tpl2, isolated from unstimulated cells, consti-
tutively phosphorylated p105 and was also autophosphorylated
(Fig. 4B, lane 2). However, this form of Tpl2 did not induce
MEK1 phosphorylation (GST-MEK1-P). LPS stimulationfailed to induce the kinase activity of Tpl2 within the p105
complex (isolated by IP using anti-p105). On the other hand,
free Tpl2 isolated by IP using anti-Tpl2 exhibited strong
MEK1-kinase activity (data not shown, Ref. [6]). These results
further support the idea that p105 functions as a competitive
inhibitor of Tpl2.
We next compared the efficiency of Tpl2-mediated phos-
phorylation of p105 and MEK1 by in vitro kinase assays. As
expected, MEK1 was phosphorylated by Tpl2 in the absence of
p105 (Fig. 4C, top panel, lane 2, GST-MEK1-P). However, in
the presence of an increasing amount of purified GST-p105
(435–969), the MEK1 phosphorylation was inhibited in a dose-
dependent manner (lanes 3–5). This effect was highly specific,
since the phosphorylation of MEK1 was not affected by a p105
mutant, 435–541, which was incapable of Tpl2 binding (Fig.
180 G.R. Babu et al. / Biochimica et Biophysica Acta 1763 (2006) 174–1813C, bottom panel) or phosphorylation by Tpl2 (Fig. 4C, lanes
7–9; also see Fig. 3C, lane 4). Concomitant with the inhibition
of MEK1 phosphorylation by GST-p105(435–969), this p105
mutant was proportionally phosphorylated by Tpl2 (upper
panel, GST-p105C-P). Notably, the phosphorylation of p105
was significantly stronger than that of MEK1, even though
more MEK1 protein was added to the kinase assay (Fig. 4C,
lanes 3–5). Thus, compared to MEK1, p105 appears to be a
more efficient substrate of Tpl2. Together, these results suggest
that p105 functions as an efficient intracomplex substrate of
Tpl2 and inhibits the MEK1-specific kinase function of Tpl2 by
preventing its access to MEK1.
4. Discussion
The nfκb1 gene product p105 serves as a physiological
partner of Tpl2 [6,10,11]. It has been shown that p105 mediates
two major functions within the Tpl2 complex: maintenance of
Tpl2 stability and inhibition of Tpl2 signaling function [6,10].
However, the molecular mechanisms underlying the p105/Tpl2
interplay are only partially understood. The data presented in
this study demonstrate that p105 does not inhibit the intrinsic
catalytic activity of Tpl2. Interestingly, when complexed with
p105, Tpl2 is catalytically active and uses p105 as an intra-
complex substrate. However, despite its strong catalytic activity,
the p105-bound Tpl2 is unable to phosphorylate its physiolog-
ical target, MEK1. Thus, p105 may be considered as a com-
petitive inhibitor of Tpl2, since it inhibits the signaling function
of Tpl2 by preventing its access to MEK1.
Signal-induced phosphorylation of p105 is known to be a
molecular trigger for its degradation by the proteasome, and this
inducible event is mediated by IKK [18–20]. The IKK phos-
phorylation sites within p105 have been mapped to a C-terminal
peptide containing serines 923, 927 and 932 [20,24,27].
Mutation of these serines either partially inhibits or completely
blocks the inducible degradation of p105 [20,24,27]. A prior
study revealed that transfected Tpl2 induces the phosphorylation
and degradation of p105 [11], but this function of Tpl2 was
thought to be indirectly mediated through activation of IKK
[24]. This assumption was based on the findings that Tpl2 does
not directly phosphorylate the C-terminal serines of p105 [11]
and that overexpressed Tpl2 induces the activity of IKK [28].
Our current study suggests that p105 serves as a direct substrate
of Tpl2. When isolated from macrophages, the p105/Tpl2
complex exhibits strong p105 kinase activity (Fig. 1). Several
lines of evidence suggest that this kinase activity is not con-
tributed by IKK. First, while the IKK activity is inducible, the
p105 kinase associated with the p105/Tpl2 complex is cons-
titutively active (Fig. 1). Second, when precipitated in the
presence of SDS, the p105/Tpl2 complex is not associated with
detectable IKK activity but remains competent in p105 phospho-
rylation (Fig. 2A). Consistently, the p105 kinase could be
isolated from IKK-deficient MEFs (Fig. 1E). Third, p105
phosphorylation within the p105/Tpl2 complex is not sensitive
to an IKK inhibitor, PS1145 (Fig. 1D). Fourth, both transfected
and in vitro translated Tpl2 induces p105 phosphorylation (Fig.
3B). Fifth, the Tpl2-induced p105 phosphorylation occurs in aregion distinct from that covering the IKK phosphorylation sites
(Fig. 3C and D). Most importantly, we have obtained genetic
evidence for the function of Tpl2 in mediating p105 phosphor-
ylation. As shown in Fig. 2C, p105 was not phosphorylated in
the immune complex isolated from Tpl2-deficient cells.
The finding that Tpl2 phosphorylates p105 within the p105/
Tpl2 complex not only establishes p105 as a direct substrate of
Tpl2 but also provides an important insight into the mechanism
of Tpl2 regulation by p105. It seems clear that p105 does not
inhibit the intrinsic catalytic activity of Tpl2. Although over-
expressed p105 partially inhibits the autophosphorylation
activity of Tpl2, this effect is associated with increased phospho-
rylation of p105. This finding suggests that p105may function as
a competitive inhibitor of Tpl2. This idea was further supported
by the finding that p105 is a much more efficient substrate of
Tpl2 compared to MEK1. Future studies will determine whether
p105 contains any specific region(s) that is involved in the
inhibition of MEK1-phosphorylating activity of Tpl2. Addi-
tionally, it is also important to examine whether the Tpl2-
mediated phosphorylation of p105 plays a priming role in IKK-
induced p105 phosphorylation and degradation.
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